WeVote
Log In

Bill

Bill

HD 3932

An Act relative to testing for Factor V Leiden

194th Legislature (2025-2026) Introduced by Danny Ryan

Establishes Factor V Leiden testing and screening requirements in Massachusetts to identify individuals at risk for dangerous blood clots early and enable preventive treatment.

0
WeVote Research Nonpartisan
Bill Summary · HD 3932

Legislative bill overview

HD 3932 would establish requirements for testing and screening of Factor V Leiden, a genetic blood clotting disorder, in Massachusetts. The bill likely mandates notification, counseling, or testing protocols for individuals at risk or identified with this condition. This follows national efforts to increase awareness and early detection of thrombophilia risk factors.

Why is this important

Factor V Leiden increases the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), which can be life-threatening if untreated. Early identification allows patients and physicians to implement preventive measures, particularly during high-risk periods like surgery, pregnancy, or prolonged immobility. Public health screening initiatives can reduce preventable blood clots and related hospitalizations.

Potential points of contention

  • Cost and implementation: Who bears the cost of testing—patients, insurers, or the state—and whether universal screening is medically or economically justified
  • Scope of testing mandate: Whether testing should be universal, targeted to specific populations, or voluntary; newborn screening programs involve different considerations than adult screening
  • Clinical utility debate: Medical experts disagree on whether identifying asymptomatic Factor V Leiden carriers changes outcomes enough to justify screening costs
  • Privacy and genetic information: Questions about data storage, insurance discrimination risks, and psychological impact of identifying a genetic predisposition

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.